Lymphir, Citius first FDA-approved product, is a reformulation of the FDA-approved cancer treatment denileukin diftitox, which combines the IL-2 cytokine and the diphtheria toxin
Small adjustments to your schedule are fine as long as they help you stay consistent with your treatment over the coming months
Unlike stimulant-based energy enhancers, these improvements stem from enhanced cellular energy production through better mitochondrial function
Tesamorelin's adverse-event profile from the Phase III program is dominated by injection-site reactions (~25% of patients), arthralgia, peripheral oedema, paresthesia, and a clinically meaningful rise in IGF-1 that occasionally exceeds the upper limit of normal
The off-period is not optional, it is part of the protocol that ensures long-term success
in 2008, the dysregulation of NRF-2 is necessary in the development of type 2 diabetes and its complications [95]